Moleculin Biotech CS (NQ: MBRX )

3.920 USD +0.060 (+1.55%)

Streaming Delayed Price Updated: 4:00 PM EDT, Jun 14, 2021 Add to My Watchlist

Price and Volume

Volume	273,895
Open	3.860
Bid (Size)	3.800 (5)
Ask (Size)	3.920 (19)
Prev. Close	3.860
Today's Range	3.840 - 3.930
52wk Range	3.120 - 9.300
Shares Outstanding	28,444,425
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

Moleculin Commences Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

May 25, 2021

- Annamycin was designed to potentially become the first ever non-cardiotoxic anthracycline and has been shown in animal models to accumulate in the lungs at more than 30 times the level of doxorubicin...

Moleculin Reports First Quarter 2021 Financial Results and Provides Programs Update

May 12, 2021

- Multiple ongoing clinical studies expected to drive key clinical and regulatory milestones throughout next 18 months -

Performance

YTD	-23.15%	-23.15%
1 Month	+17.72%	+17.72%
3 Month	-12.30%	-12.30%
6 Month	-15.15%	-15.15%
1 Year	-41.67%	-41.67%

More News

Moleculin Biotech to Present at the Q2 Virtual Investor Summit

May 11, 2021

WPD Pharmaceuticals to Receive $6.7 Million Grant for Development of Annamycin Drug Candidate

May 11, 2021

Moleculin Awarded New Rare Pediatric Disease Designation from U.S. FDA for WP1066 for the Treatment of Ependymoma

April 14, 2021

Moleculin Engages IQVIA to Manage Potential COVID-19 Clinical Trial

April 06, 2021

Moleculin Receives FDA Approval of Fast Track Designation for Annamycin in the Treatment of Sarcoma Lung Metastases

March 30, 2021

Moleculin Biotech to Start Testing Annamycin in Sarcoma Lung Metastases Patients

May 25, 2021

Moleculin Biotech, Inc. Reports Financial Results for the Year Ended December 31, 2020

March 24, 2021

Moleculin to Participate in Four Upcoming Healthcare Conferences

March 09, 2021

Moleculin Biotech Stock Is Trading Higher After WP1066 Scores Rare Pediatric Disease Tag For Type Of Brain Tumor

April 14, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.